ATE318896T1 - Rekombinante rna-replikase von hepatitis-c-virus - Google Patents

Rekombinante rna-replikase von hepatitis-c-virus

Info

Publication number
ATE318896T1
ATE318896T1 AT96933178T AT96933178T ATE318896T1 AT E318896 T1 ATE318896 T1 AT E318896T1 AT 96933178 T AT96933178 T AT 96933178T AT 96933178 T AT96933178 T AT 96933178T AT E318896 T1 ATE318896 T1 AT E318896T1
Authority
AT
Austria
Prior art keywords
hcv
rdrp
hepatitis
virus
vitro
Prior art date
Application number
AT96933178T
Other languages
English (en)
Inventor
Curt H Hagedorn
Reinoldus H Al
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE318896T1 publication Critical patent/ATE318896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96933178T 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus ATE318896T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US438395P 1995-09-27 1995-09-27

Publications (1)

Publication Number Publication Date
ATE318896T1 true ATE318896T1 (de) 2006-03-15

Family

ID=21710540

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933178T ATE318896T1 (de) 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus

Country Status (8)

Country Link
US (2) US5981247A (de)
EP (1) EP0859833B1 (de)
JP (1) JP4191797B2 (de)
AT (1) ATE318896T1 (de)
AU (1) AU719122B2 (de)
CA (1) CA2233309A1 (de)
DE (1) DE69635864T2 (de)
WO (1) WO1997012033A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
FR2761695B1 (fr) 1997-04-04 1999-09-24 Bio Merieux Arn polymerase fonctionnant preferentiellement sur matrice d'arn, sa preparation et son utilisation
DE69838513T2 (de) * 1997-12-11 2008-07-03 Smithkline Beecham Corp. Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren
EP1058686B1 (de) 1998-02-25 2006-11-02 Emory University 2'-fluoronukleoside
EP1068362A4 (de) * 1998-04-02 2005-07-20 Viropharma Inc Hepatitis c virus ns5b zusammensetzungen und verfahren zu deren verwendung
AU4393399A (en) * 1998-06-24 2000-01-10 Chugai Seiyaku Kabushiki Kaisha Hcv-derived rna polymerase gene
AU2181800A (en) * 1998-12-10 2000-06-26 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
EP1634888A3 (de) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthese von 2'-Deoxy-L-Nukleosiden
AU764095B2 (en) * 2000-04-07 2003-08-07 Shionogi & Co., Ltd. Preincubation assay method
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
GB0029539D0 (en) * 2000-12-04 2001-01-17 Isis Innovation Method for identifying modulatorss of transcription
EP1360276A4 (de) * 2001-01-31 2004-12-15 Bristol Myers Squibb Pharma Co In-vitro-system zur replikation rna-abhängiger rna-polymerase-viren (rdrp-viren)
WO2002095002A2 (en) * 2001-05-22 2002-11-28 University Of Chicago N4 virion single-stranded dna dependent rna polymerase
CA2460819A1 (en) * 2001-09-18 2003-03-27 Affinium Pharmaceuticals, Inc. Methods and apparatuses for purification
WO2003027330A1 (en) * 2001-09-25 2003-04-03 Xencor Rna dependent rna polymerase mediated protein evolution
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Ｈｃｖ 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
WO2003044168A2 (en) * 2001-11-16 2003-05-30 University Of Massachusetts Facilitation of rna interference
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
BRPI0419345B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc uso do (2’r)-2’-desoxi-2’-flúor-2’-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
DK1658302T3 (da) 2003-07-25 2010-11-22 Idenix Pharmaceuticals Inc Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
EP1711516A4 (de) * 2004-01-09 2009-12-30 Merck & Co Inc Hcv-rna-abhängige rna-polymerase
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
BRPI0607770A2 (pt) 2005-02-28 2009-06-13 Genelabs Tech Inc compostos de nucleosideo tricìclico para tratamento de infecções virais
TW200720285A (en) 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2010014134A1 (en) 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2166016A1 (de) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidat-Derivate von Nukleosiden
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011023801A1 (en) 2009-08-31 2011-03-03 F. Hoffmann-La Roche Ag Hcv ns3/4a replicon shuttle vectors
BR112012011221A2 (pt) 2009-11-14 2016-04-05 Hoffmann La Roche biomarcadores para prever resposta rápida ao tratamento de hcv
CN102656459A (zh) 2009-12-02 2012-09-05 弗·哈夫曼-拉罗切有限公司 用于预测对hcv治疗持续应答的生物标志物
US20110245328A1 (en) 2010-03-31 2011-10-06 Hyunsoon Kang HCV NS5A Replicon Shuttle Vectors
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
TWI515000B (zh) 2010-04-01 2016-01-01 伊迪尼克製藥公司 用於治療病毒感染之化合物及醫藥組合物
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
AU2011281546B2 (en) 2010-07-22 2014-07-10 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal

Also Published As

Publication number Publication date
DE69635864D1 (de) 2006-04-27
WO1997012033A1 (en) 1997-04-03
JP4191797B2 (ja) 2008-12-03
DE69635864T2 (de) 2006-10-26
EP0859833A4 (de) 2001-03-28
US5981247A (en) 1999-11-09
EP0859833B1 (de) 2006-03-01
EP0859833A1 (de) 1998-08-26
JPH11514862A (ja) 1999-12-21
AU719122B2 (en) 2000-05-04
AU7200796A (en) 1997-04-17
US6248589B1 (en) 2001-06-19
CA2233309A1 (en) 1997-04-03

Similar Documents

Publication Publication Date Title
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
Borman et al. elF4G and its proteolytic cleavage products: effect on initiation of protein synthesis from capped, uncapped, and IRES-containing mRNAs.
Kessler et al. Bone morphogenetic protein-1: the type I procollagen C-proteinase
Wirth et al. How a single Sindbis virus mRNA directs the synthesis of one soluble protein and two integral membrane glycoproteins
Denkewalter et al. Total synthesis of an enzyme. I. Objective and strategy
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
WO2021261577A1 (ja) 改変された遺伝暗号表を有する翻訳系
Barth et al. The oligomerization reaction of the Semliki Forest virus membrane protein subunits.
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
GB9722320D0 (en) Human cell cycle checkpoint proteins
GB9810999D0 (en) Materials and methods relating to the expression of genes
WO1990003435A3 (fr) Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle
Hansen et al. Presence of the cap-binding protein in initiation factor preparations from poliovirus-infected HeLa cells
Tanese et al. Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase
Robert et al. Interactions with tRNALys induce important structural changes in human immunodeficiency virus reverse transcriptase
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
AP2368A (en) Novel expression vectors and uses thereof.
Skoging-Nyberg et al. MXI motif of Semliki Forest virus capsid protein affects nucleocapsid assembly
GR3007909T3 (de)
EP0282330A3 (de) Verfahren zur Stimulierung der Genexpression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties